论文部分内容阅读
目的:观察脑梗死二级预防中抗血小板药物生化抵抗的发生与复发的相关性。方法:选取佛山市高明区人民医院2015年8月至2017年2月收治的脑梗死患者190例,根据随机数表法分为对照组及观察组,各95例。对照组使用阿司匹林,观察组使用氯吡格雷。观察比较两组治疗1年后抗血小板药物生化抵抗发生率及脑梗死复发率。结果:对照组抵抗总发生率为43.16%,高于观察组,组间比较,差异具有统计学意义(P<0.05);对照组脑梗死复发率为30.53%,与观察组比较,差异无统计学意义(P>0.05)。结论:脑梗死患者使用阿司匹林或氯吡格雷治疗均存在一定比例的药物生化抵抗,且患者发生生化抵抗后复发急性脑梗死风险大,因此临床治疗脑梗死时,应注意药物的选用,必要时可在抗血小板药物基础上联合其他药物使用,对减少抗血小板药物生化抵抗及疾病复发有着重要的指导意义。
Objective: To observe the relationship between the occurrence and recurrence of antiplatelet biochemical resistance in secondary prevention of cerebral infarction. Methods: Totally 190 patients with cerebral infarction who were treated in Gaoming District People’s Hospital of Foshan City from August 2015 to February 2017 were divided into control group and observation group according to the random number table method, 95 cases each. The control group used aspirin, and the observation group used clopidogrel. The incidences of antiplatelet drugs biochemical resistance and the recurrence rate of cerebral infarction were compared between two groups after one year of treatment. Results: The total incidence of resistance in the control group was 43.16%, which was higher than that in the observation group. There was significant difference between the two groups (P <0.05). The recurrence rate of the control group was 30.53% Significance (P> 0.05). Conclusion: Aspirin or clopidogrel treatment in patients with cerebral infarction have a certain proportion of drug biochemical resistance, and patients with a high risk of recurrent acute cerebral infarction after biochemical resistance, so the clinical treatment of cerebral infarction, we should pay attention to the choice of drugs, if necessary In combination with other drugs on the basis of anti-platelet drugs, it has important guiding significance for reducing the anti-platelet drug biochemical resistance and disease recurrence.